Abstract
Congenital hyperinsulinism (HI) is defined as being “diazoxide-unresponsive” if the hypoglycemia persists despite maximum doses of diazoxide for at least five days . Inactivating mutations in the genes encoding the two subunits of the beta-cell ATP-sensitive potassium (KATP) channel are the most frequent cause of diazoxide-unresponsive hyperinsulinism. Children with KATPHI typically present at birth with severe hypoglycemia. Genetic testing can be used to identify children with focal KATPHI and 18F-DOPA-PET imaging aids with focal lesion localization for curative surgery. A less common form of diazoxide-unresponsive HI is caused by activating mutations in glucokinase (GCK). Clinical phenotypes in children with GCK HI vary, but may be diazoxide-unresponsive and medically uncontrollable, requiring pancreatectomy. Approximately ten percent of diazoxide-unresponsive HI cases are of unknown genetic etiology. The overall goal in the management of infants with diazoxide-unresponsive HI is to identify those with focal HI and to find an effective treatment regimen for those that cannot be cured by surgery (diffuse HI).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- 18F-DOPA:
-
18Fluoro-dihydroxyphenylalanine
- GCK:
-
Glucokinase
- GCK-HI:
-
Glucokinase hyperinsulinism
- HI:
-
Congenital hyperinsulinism
- HI:
-
Hyperinsulinism
- KATP :
-
ATP-sensitive potassium channel
- Kir6.2:
-
Inwardly rectifying potassium channel subunit (encoded by KCNJ11)
- LINE:
-
Localized islet cell nuclear enlargement
- PET:
-
Positron emission tomography
- SUR1:
-
Sulfonylurea receptor 1 (regulatory subunit encoded by ABCC8)
References
Bellanne-Chantelot C, et al. ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism. J Med Genet. 2010;47:752–9. https://doi.org/10.1136/jmg.2009.075416.
Snider KE, et al. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab. 2013;98:E355–63. https://doi.org/10.1210/jc.2012-2169.
Nessa A, Rahman SA, Hussain K. Hyperinsulinemic hypoglycemia - the molecular mechanisms. Front Endocrinol (Lausanne). 2016;7:29. https://doi.org/10.3389/fendo.2016.00029.
Li C, et al. Functional and metabolomic consequences of KATP channel inactivation in human islets. Diabetes. 2017;66:1901–13. https://doi.org/10.2337/db17-0029.
Macmullen CM, et al. Diazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the beta-cell sulfonylurea receptor SUR1. Diabetes. 2011;60:1797–804. https://doi.org/10.2337/db10-1631.
Pinney SE, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118:2877–86. https://doi.org/10.1172/JCI35414.
Grimberg A, et al. Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes. 2001;50:322–8.
Lord K, Dzata E, Snider KE, Gallagher PR, De Leon DD. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocrinol Metab. 2013;98:E1786–9. https://doi.org/10.1210/jc.2013-2094.
Nessa A, Rahman SA, Hussain K. Hyperinsulinemic hypoglycemia – the molecular mechanisms. Front Endocrinol (Lausanne). 2016;7:29. https://doi.org/10.3389/fendo.2016.00029.
Fourtner SH, Stanley CA, Kelly A. Protein-sensitive hypoglycemia without leucine sensitivity in hyperinsulinism caused by K(ATP) channel mutations. J Pediatr. 2006;149:47–52., doi:S0022-3476(06)00129-6 [pii]. https://doi.org/10.1016/j.jpeds.2006.02.033.
Steinkrauss L, et al. Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism. J Pediatr Nurs. 2005;20:109–18., doi:S0882596304002076 [pii]. https://doi.org/10.1016/j.pedn.2004.12.009.
Lord K, et al. High risk of diabetes and neurobehavioral deficits in individuals with surgically treated hyperinsulinism. J Clin Endocrinol Metab. 2015;100:4133–9. https://doi.org/10.1210/jc.2015-2539.
Beltrand J, et al. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care. 2012;35:198–203. https://doi.org/10.2337/dc11-1296.
Christesen HB, et al. Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol. 2008;159:27–34. https://doi.org/10.1530/eje-08-0203.
Martinez R, et al. Heterogeneity in phenotype of hyperinsulinism caused by activating glucokinase mutations: a novel mutation and its functional characterization. Clin Endocrinol. 2017;86:778–83. https://doi.org/10.1111/cen.13318.
Sogno Valin P, et al. Genetic analysis of Italian patients with congenital hyperinsulinism of infancy. Horm Res Paediatr. 2013;79:236–42. https://doi.org/10.1159/000350827.
Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes. 1990;39:647–52.
Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes. 1996;45:223–41.
Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov. 2009;8:399–416. https://doi.org/10.1038/nrd2850.
Matschinsky FM, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes. 2006;55:1–12.
Basco D, et al. Alpha-cell glucokinase suppresses glucose-regulated glucagon secretion. Nat Commun. 2018;9:546. https://doi.org/10.1038/s41467-018-03034-0.
Christesen HB, et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes. 2002;51:1240–6.
Glaser B, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med. 1998;338:226–30. https://doi.org/10.1056/NEJM199801223380404.
Davis EA, et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia. 1999;42:1175–86. https://doi.org/10.1007/s001250051289.
Vionnet N, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature. 1992;356:721–2. https://doi.org/10.1038/356721a0.
Njolstad PR, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med. 2001;344:1588–92. https://doi.org/10.1056/nejm200105243442104.
Ajala ON, Huffman DM, Ghobrial II. Glucokinase mutation-a rare cause of recurrent hypoglycemia in adults: a case report and literature review. J Commun Hosp Intern Med Perspect. 2016;6:32983. https://doi.org/10.3402/jchimp.v6.32983.
Barbetti F, et al. Opposite clinical phenotypes of glucokinase disease: description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene. Mol Endocrinol (Baltimore, MD.). 2009;23:1983–9. https://doi.org/10.1210/me.2009-0094.
Beer NL, et al. Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans. J Biol Chem. 2011;286:19118–26. https://doi.org/10.1074/jbc.M111.223362.
Challis BG, et al. Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation. Clin Endocrinol. 2014;81:855–61. https://doi.org/10.1111/cen.12517.
Christesen HB, Brusgaard K, Beck Nielsen H, Brock Jacobsen B. Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: hypoglycaemia unawareness and attacks. Clin Endocrinol. 2008;68:747–55. https://doi.org/10.1111/j.1365-2265.2008.03184.x.
Cuesta-Munoz AL, et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes. 2004;53:2164–8.
Dullaart RP, Hoogenberg K, Rouwe CW, Stulp BK. Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene. J Intern Med. 2004;255:143–5.
Gloyn AL, et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes. 2003;52:2433–40.
Henquin JC, et al. Congenital hyperinsulinism caused by hexokinase I expression or glucokinase-activating mutation in a subset of beta-cells. Diabetes. 2013;62:1689–96. https://doi.org/10.2337/db12-1414.
Kassem S, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med. 2010;362:1348–50. https://doi.org/10.1056/NEJMc0909845.
Meissner T, et al. Diagnostic difficulties in glucokinase hyperinsulinism. Horm Metab Res = Hormon- Stoffwechselforschung = Horm Metab. 2009;41:320–6. https://doi.org/10.1055/s-0028-1102922.
Morishita K, Kyo C, Yonemoto T. Asymptomatic congenital hyperinsulinism due to a glucokinase-activating mutation, treated as adrenal insufficiency for twelve years. Case Rep Endocrinol. 2017;2017:4709262. https://doi.org/10.1155/2017/4709262.
Rozenkova K, et al. High incidence of heterozygous ABCC8 and HNF1A mutations in Czech patients with congenital hyperinsulinism. J Clin Endocrinol Metab. 2015;100:E1540–9. https://doi.org/10.1210/jc.2015-2763.
Sayed S, et al. Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. Diabetes. 2009;58:1419–27. https://doi.org/10.2337/db08-1792.
Wabitsch M, et al. Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabet Med J Br Diabet Assoc. 2007;24:1393–9. https://doi.org/10.1111/j.1464-5491.2007.02285.x.
Grimsby J, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003;301:370–3. https://doi.org/10.1126/science.1084073.
Xu J, et al. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 diabetes mellitus. Bioorg Med Chem Lett. 2017;27:2069–73. https://doi.org/10.1016/j.bmcl.2016.10.085.
Lloyd DJ, et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature. 2013;504:437–40. https://doi.org/10.1038/nature12724.
Zelent B, et al. Mutational analysis of allosteric activation and inhibition of glucokinase. Biochem J. 2011;440:203–15. https://doi.org/10.1042/BJ20110440.
Sempoux C, et al. Morphological mosaicism of the pancreatic islets: a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy. J Clin Endocrinol Metab. 2011;96:3785–93. https://doi.org/10.1210/jc.2010-3032.
Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54:3592–601.
Capito C, et al. The surgical management of atypical forms of congenital hyperinsulinism. Semin Pediatr Surg. 2011;20:54–5. https://doi.org/10.1053/j.sempedsurg.2010.10.003.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rayannavar, A., Christesen, H.T., De León-Crutchlow, D.D. (2019). Diazoxide-Unresponsive Forms of Congenital Hyperinsulinism. In: De León-Crutchlow, D., Stanley, C. (eds) Congenital Hyperinsulinism. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-030-02961-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-02961-6_3
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-030-02960-9
Online ISBN: 978-3-030-02961-6
eBook Packages: MedicineMedicine (R0)